Shameem Abbasy, MD
Urogynecology and Reconstructive Pelvic Surgery · Chicago, ILNPI 1063425965
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.9% of the total across 54 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AbbVie at 35.3% of the total. Reporting peaked in 2019 at $458 and has fallen 62.0% since, to $174 in 2025. That places this record below the midpoint for urogynecology and reconstructive pelvic surgery clinicians in IL, where the typical reported total is $2,778.
Across 54 payments — averaging $25.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$488
- Boston Scientific$121
- Coloplast$110
- Coopersurgical, Inc.$75
- Conmed Corporation$71
- Aspira Women's Health Inc$68
- plus $448 from 18 others
What the payments were for
- Food & beverage$1,28493%
- Education$987%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 18 | $488 |
| Boston Scientific | 1 | $121 |
| Coloplast | 3 | $110 |
| Coopersurgical, Inc. | 4 | $75 |
| Conmed Corporation | 1 | $71 |
| Aspira Women's Health Inc | 3 | $68 |
| Axonics, Inc. | 2 | $43 |
| Astellas Pharma US Inc | 2 | $41 |
| Exeltis, USA Inc. | 2 | $36 |
| Convatec Inc. | 2 | $36 |
| Medtronic | 1 | $29 |
| Therapeuticsmd, Inc. | 2 | $29 |
| Pfizer | 1 | $29 |
| Merck | 2 | $29 |
| Pacira Pharmaceuticals Incorporated | 1 | $23 |
| Novo Nordisk | 1 | $23 |
| Agile Therapeutics, Inc. | 1 | $19 |
| 180 Medical, Inc. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Hologic Sales And Service, LLC | 1 | $15 |
| Vertex | 1 | $15 |
| Laborie Medical Technologies Corp. | 1 | $15 |
| Organon | 1 | $14 |
| Abbott | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLYX$121
How this compares
$1,382 in reported general payments places this provider in the 25th percentile of 62 urogynecology and reconstructive pelvic surgery providers in Illinois.
See all urogynecology and reconstructive pelvic surgery providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 62 | $43,253 |
| MyrbetriqMirabegron | 42 | $26,666 |
| Estradiol | 53 | $3,379 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 16 | $2,998 |
| Trimethoprim | 68 | $2,641 |
| Clobetasol Propionate | 17 | $160 |
| Triamcinolone Acetonide | 12 | $57 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $39 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $41 | $26,66642 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 62 urogynecology and reconstructive pelvic surgery providers in Illinois.
Other urogynecology and reconstructive pelvic surgery in Chicago
- Abraham ShashouaChicago$339K
- Akira GillinghamChicago$58K
- Kimberly KentonChicago$43K
- Traci BeckChicago$32K
- Margaret MuellerChicago$26K
- Carol BretschneiderChicago$14K
- Trieu DoChicago$11K
- Sean GeorgeChicago$9K
- Thythy PhamChicago$8K
- Ankita GuptaChicago$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.